September 10, 2025Annals of HematologyOpen Access

Unicentric Castleman disease treated with rituximab before surgery: clinicopathologic findings

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Observational study reveals partial response to rituximab in unicentric Castleman disease, suggesting microenvironment impacts treatment efficacy.

Partial response to rituximab therapy was observed in a unicentric Castleman disease case, highlighting treatment challenges.
Clinical findings, including unique histological features, were observed in the surgical specimen after rituximab treatment.
Neoadjuvant therapy with anti-CD20 showed only a limited impact, indicating complexities related to the local microenvironment.
Complete surgical excision remains the standard care for unicentric Castleman disease while exploring alternative therapies.

Paulli et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational study reveals partial response to rituximab in unicentric Castleman disease, suggesting microenvironment impacts treatment efficacy.